NorthStar Medical Radioisotopes to Host Groundbreaking and Speaker Event Featuring Representatives from U.S. Department of Energy’s National Nuclear Security Administration, State of Wisconsin and Industry Experts
--(BUSINESS WIRE)--Sep 13, 2019--
NorthStar Medical Radioisotopes:
NorthStar Medical Radioisotopes will host a ribbon-cutting, groundbreaking and speakers event, “ Molybdenum-99: Domestic Radioisotope Production Now, Expansion for the Future,” at NorthStar corporate headquarters in Beloit, Wis. The event will mark nearly a year of continuous domestic Mo-99 supply for U.S. healthcare providers, demonstrate progress on NorthStar’s expansion plans and discuss current and future U.S. supply of important medical radioisotopes.
Media are invited to attend and photography/videography is permitted.
NorthStar Medical Radioisotopes Corporate Headquarters
1800 Gateway Boulevard, Beloit, Wisconsin 53511
Thursday, September 19, 2019. Reporters are invited to attend from 10:15 – 11:30 a.m. for the groundbreaking ceremony and speaker discussions. Media tours are available; please inquire at registration.
Please plan to arrive at 10 a.m. to check in.
NorthStar’s RadioGenix ® System (technetium 99m generator) is an innovative, high technology platform that is approved and commercially available to produce technetium-99m (Tc-99m), a widely used medical radioisotope important for over 40,000 patients on a daily basis in the United States who require diagnostic imaging tests. Tc-99m is obtained from another radioisotope, molybdenum 99 (Mo-99). The proprietary RadioGenix System uses U.S.-produced, non-uranium based material and an environmentally friendly production process to produce Tc-99m rather than overseas, uranium-based production. Before RadioGenix technology became available, the supply of Mo-99 in the United States has experienced frequent and sometimes severe interruptions which negatively impact patient healthcare. The RadioGenix System is the first and only automated isotope separation system of its kind for use with non-uranium based Mo-99, and is designed to help alleviate shortage situations and expand domestic radioisotope supply for patients needing important diagnostic imaging tests.
For more information or if you are a reporter interested in attending, please contact Priscilla Harlan on behalf of NorthStar Medical Radioisotopes, telephone (781) 799-7917, or firstname.lastname@example.org.
Indication and Important Risk Information about the RadioGenix ® System and Sodium Pertechnetate Tc 99m Injection USP
The RadioGenix ® System is a technetium Tc-99m generator used to produce Sodium Pertechnetate Tc 99m Injection, USP. Sodium Pertechnetate Tc 99m Injection is a radioactive diagnostic agent and can be used in the preparation of FDA-approved diagnostic radiopharmaceuticals.
Sodium Pertechnetate Tc 99m Injection is also indicated in
IMPORTANT RISK INFORMATION
To report SUSPECTED ADVERSE REACTIONS, contact NorthStar Medical Radioisotopes, LLC at 1-844-438-6659; or FDA at 1-800-332-1088 or http://www.fda.gov/medwatch.
For Full RadioGenix ® System Prescribing Information, click here or visithttps://www.northstarnm.com/wp-content/uploads/2019/08/radiogenix-system-pi-july2019.pdf.
View source version on businesswire.com:https://www.businesswire.com/news/home/20190913005349/en/
CONTACT: NorthStar Medical Radioisotopes
Priscilla Harlan, (781) 799-7917
KEYWORD: WISCONSIN UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: RESEARCH BIOTECHNOLOGY OTHER HEALTH RADIOLOGY PHARMACEUTICAL HEALTH SCIENCE
SOURCE: NorthStar Medical Radioisotopes
Copyright Business Wire 2019.
PUB: 09/13/2019 10:53 AM/DISC: 09/13/2019 10:52 AM